The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer.
Maria Rovithi
No relevant relationships to disclose
Joline S. Lind
No relevant relationships to disclose
Thang V Pham
No relevant relationships to disclose
Jaco C Knol
No relevant relationships to disclose
Henk M.W. Verheul
No relevant relationships to disclose
Egbert F Smit
No relevant relationships to disclose
Connie R. Jimenez
No relevant relationships to disclose